Insulet acquires assets of Automated Glucose Control for $25M

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet¬†(Nasdaq:PODD) announced today that it acquired the assets of Automated Glucose Control, a developer of insulin delivery technology.

This marks the second asset buy in as many days for Insulet. Yesterday, the company picked up automated insulin delivery patents from Bigfoot Biomedical. Both acquisitions cost the company $25 million.

Palo Alto, California-based Automated Glucose Control (ACG) focuses on developing and commercializing best-in-class automated insulin delivery (AID) technology. Insulet develops its own AID platform, with the Omnipod 5 representing the latest iteration, having received FDA clearance last year.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0